Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aethlon Medical (AEMD) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Aethlon Medical (AEMD) over the last 14 years, with Q1 2025 value amounting to -$4.1 million.

  • Aethlon Medical's Gains from Investment Securities fell 111363.45% to -$4.1 million in Q1 2025 from the same period last year, while for Mar 2025 it was -$4.0 million, marking a year-over-year decrease of 104462.69%. This contributed to the annual value of -$4.0 million for FY2025, which is 211381.7% down from last year.
  • According to the latest figures from Q1 2025, Aethlon Medical's Gains from Investment Securities is -$4.1 million, which was down 111363.45% from $7073.0 recorded in Q4 2024.
  • In the past 5 years, Aethlon Medical's Gains from Investment Securities ranged from a high of $400806.0 in Q1 2024 and a low of -$4.1 million during Q1 2025
  • Over the past 5 years, Aethlon Medical's median Gains from Investment Securities value was $8872.5 (recorded in 2023), while the average stood at -$227201.6.
  • In the last 5 years, Aethlon Medical's Gains from Investment Securities soared by 123551.35% in 2021 and then crashed by 142511.04% in 2023.
  • Quarter analysis of 5 years shows Aethlon Medical's Gains from Investment Securities stood at $13557.0 in 2021, then crashed by 86.1% to $1884.0 in 2022, then skyrocketed by 397.51% to $9373.0 in 2023, then dropped by 24.54% to $7073.0 in 2024, then crashed by 57539.67% to -$4.1 million in 2025.
  • Its Gains from Investment Securities stands at -$4.1 million for Q1 2025, versus $7073.0 for Q4 2024 and $3832.0 for Q3 2024.